Clinical trials
Recurrent or Metastatic Nasopharyngeal Carcinoma clinical trials
Below are recruiting recurrent or metastatic nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 2,322 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06851247RecruitingPhase 2
Chemoradiation plus toripalimab for advanced nasopharyngeal cancer
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
Guangzhou, GuangdongAges 18–65 - NCT07328841RecruitingPhase 3
Lower radiation dose study for advanced nasopharyngeal cancer
This trial compares a lower dose of radiation to the standard dose for people with advanced nasopharyngeal cancer that shrank after chemotherapy and immunotherapy. The goal is to see if a lower dose works just as well with fewer side effects.
Guangzhou, GuangdongAges 18–70 - NCT06900647RecruitingPhase 1
Bortezomib plus cisplatin for advanced breast cancer
This study tests a combination of two drugs, bortezomib and cisplatin, for people with breast cancer that has spread or come back after standard treatments. The goal is to see if this combination can help shrink or control the cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06502743RecruitingPhase 2
Study of chemotherapy and pembrolizumab with or without nesuparib for endometrial cancer
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
Kyeonggi-doAges 19 years+ - NCT07226856RecruitingPhase 2
New combo for advanced pancreatic cancer
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
Scottsdale, ArizonaAges 18 years+ - NCT07213934RecruitingPhase 1/Phase 2
Immunotherapy and radiation before surgery for recurrent head and neck cancer
This trial tests a new combination for people whose head and neck cancer has come back after prior radiation. You'll receive an immunotherapy drug (pembrolizumab) plus radiation, then surgery. The goal is to see if this approach can improve how well surgery works.
Cincinnati, OhioAges 18 years+ - NCT07144826RecruitingEarly Phase 1
Probiotic for Gut and Vaginal Health in Ovarian Cancer Chemotherapy
This trial tests whether taking a probiotic supplement can help balance the bacteria in your gut and vagina while you undergo chemotherapy for advanced ovarian cancer. It aims to see if this could improve your treatment experience or outcomes.
Columbus, OhioAges 18 years+ - NCT07034053RecruitingPhase 1/Phase 2
Clofarabine for advanced bladder cancer
This trial tests the drug clofarabine in people with advanced bladder cancer that has spread or cannot be removed by surgery. It is for those who have already tried standard treatments or chose not to have them.
ViennaAges 18 years+ - NCT05838066RecruitingPhase 3
KN026 plus HB1801 for HER2-positive advanced breast cancer
This Phase 3 study tests whether taking KN026 with HB1801 as first treatment works better and is safe for people with HER2-positive breast cancer that has come back or spread. It may help by improving tumor response and delaying progression compared with the study’s treatment plan.
Beijing, chaoyangAges 18 years+ - NCT07000643RecruitingPhase 3
Proton vs. standard radiation for nasopharyngeal cancer
This trial compares two types of radiation therapy—proton beam versus standard X-ray (photon)—for treating nasopharyngeal cancer. The goal is to see if proton therapy works as well as standard therapy while possibly causing fewer side effects.
JinanAges 18–75 - NCT06859775RecruitingPhase 1/Phase 2
SHR-A1811 combination for recurrent or metastatic cervical cancer
This study tests whether a new drug combination called SHR-A1811 can help people with cervical cancer that has come back or spread. It aims to find a better treatment option for those who have limited choices.
Beijing, Beijing MunicipalityAges 18–75 - NCT06964009RecruitingPhase 1
New drug plus paclitaxel for resistant ovarian cancer
This trial tests a new drug called DT2216 combined with the chemotherapy drug paclitaxel for ovarian cancer that has stopped responding to platinum-based chemo. The goal is to see if this combination can shrink or slow the cancer, and to find a safe dose.
Boston, MassachusettsAges 18 years+ - NCT06954116RecruitingPhase 2
Iparomlimab and Tuvonralimab before surgery for liver cancer
This trial tests two drugs given before surgery to people with liver cancer that has a high chance of coming back. The goal is to see if the drugs can shrink the tumor and lower the risk of recurrence.
Wuhan, HubeiAges 18–75 - NCT06947928RecruitingPhase 2/Phase 3
Vaccine plus immunotherapy for Merkel cell cancer
This trial tests an experimental vaccine (IFx-Hu2.0) followed by the immunotherapy drug pembrolizumab in people with advanced Merkel cell carcinoma who have not been treated with checkpoint inhibitors before. The goal is to see if this combination helps shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06940440RecruitingPhase 1
IFx-Hu2.0 with pembrolizumab for advanced Merkel cell carcinoma
This trial tests a new drug, IFx-Hu2.0, given alongside the immunotherapy pembrolizumab (Keytruda) for people with advanced or spreading Merkel cell carcinoma (MCC). The goal is to see if the combination helps shrink tumors and slow the disease.
Tampa, FloridaAges 18 years+ - NCT06906562RecruitingPhase 2
Pemigatinib for advanced pancreatic cancer with FGFR changes
This trial tests a targeted pill, pemigatinib, for people with advanced pancreatic cancer that has a specific FGFR gene change. The study is done entirely through telemedicine, so you can participate from home if eligible.
Birmingham, AlabamaAges 18 years+ - NCT06873763RecruitingPhase 1/Phase 2
Nelmastobart with chemo for advanced colorectal cancer
This trial tests a new immunotherapy drug, nelmastobart, combined with two standard chemotherapy drugs (trifluridine/tipiracil and bevacizumab) for people with advanced colorectal cancer that hasn't responded to other treatments. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT06839066RecruitingPhase 2
HLX43 for advanced nasopharyngeal cancer after prior treatments
This trial tests an investigational drug called HLX43 for people with nasopharyngeal cancer that has come back or spread, and who have already tried two or more prior treatments without success. The goal is to see if HLX43 can shrink tumors or slow the cancer's growth.
Fuzhou, FujianAges 18 years+ - NCT05147844RecruitingPhase 2
Toripalimab plus radiation for limited-spread nose cancer
This Phase 2 trial studies whether adding toripalimab (an immune therapy) to radiation can control nasopharyngeal cancer that has spread only to a few places. It may help by boosting the immune system while the radiation treats the tumor sites.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06805617RecruitingPhase 2
Ivonescimab for advanced salivary gland cancer
This trial tests a new drug called Ivonescimab for people with advanced salivary gland cancer that has spread or cannot be removed surgically. The goal is to see if the drug can shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT06771193Recruiting
Study of cervical cancer treatment patterns in Italy
This study looks at the types of treatments and disease characteristics in people with cervical cancer that is locally advanced (cannot be removed by surgery) or has come back or spread. It may help doctors understand how different treatments are used in Italy.
Bologna, BolognaAges 18 years+ - NCT06699212RecruitingPhase 3
Light-activated therapy with immunotherapy for head and neck cancer
This trial tests a new light-activated treatment (ASP-1929) combined with an immunotherapy drug (pembrolizumab) as a first treatment for head and neck cancer that has come back in the same area but has not spread to other parts of the body. It aims to see if this combination works better than standard treatment alone.
Duarte, CaliforniaAges 18 years+ - NCT06583070Recruiting
SABR plus targeted therapy and immunotherapy for advanced kidney cancer
This trial tests combining a precise type of radiation (SABR) with standard targeted therapy and immunotherapy drugs for kidney cancer that has come back or spread. The goal is to see if adding radiation improves outcomes.
Beijing, Beijing MunicipalityAges 18–85 - NCT06509009RecruitingPhase 2
Nimotuzumab and TGP for first-line recurrent / metastatic nasopharyngeal cancer
This trial tests a combination of two drugs—nimotuzumab (a targeted therapy) and TGP (a chemotherapy)—as a first treatment for people whose nasopharyngeal cancer has returned or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Recurrent or Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 2,322 recruiting recurrent or metastatic nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Recurrent Nasopharyngeal Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Nasopharyngeal Carcinoma
- Metastatic Nasopharyngeal Squamous Cell Carcinoma
- Recurrent Nasopharyngeal Squamous Cell Carcinoma
- Nasopharyngeal Carcinoma
- Metastatic Renal Cell Carcinoma
- Nasopharyngeal Carcinoma (NPC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.